Elevated Polyreactive Immunoglobulin G in Immune-Mediated Liver Injuries With the Need for Immunosuppressive Therapy [0.03%]
自身免疫性肝病患者中需要免疫抑制治疗患者的多反应性免疫球蛋白G升高
Theresa Kirchner,George N Dalekos,Kalliopi Zachou et al.
Theresa Kirchner et al.
Background & aims: The distinction of drug-induced liver injury (DILI), drug-induced autoimmune-like hepatitis (DI-ALH), and autoimmune hepatitis (AIH) can be challenging due to overlapping clinical characteristics. Recen...
Alessandro Mantovani,Danila Capoccia,Valeria Guglielmi et al.
Alessandro Mantovani et al.
A Novel Zebrafish Liver-Specific Metastasis Model Reveals c-Met as a Driver of Liver Tropism [0.03%]
一个新的肝特异性转移斑马鱼模型揭示了c-Met是决定肝脏趋向性的驱动因素
Merve Basol,Peyda Korhan,Helin Ozaktas et al.
Merve Basol et al.
Background and aims: Intrahepatic metastasis negatively impacts the prognosis of several cancers, including hepatocellular and colorectal carcinoma. Zebrafish larval xenografts serve as a robust vertebrate platform that a...
Preventing First and Further Decompensation in Advanced Chronic Liver Disease [0.03%]
重症慢性肝病患者的一级和二级预防以避免失代偿事件发生
Leonardo Corrêa Süffert,Bernardo de Faria Moraes,Guilherme Grossi Lopes Cançado
Leonardo Corrêa Süffert
Advanced chronic liver disease (ACLD) remains a major cause of global morbidity and mortality. Preventing hepatic decompensation-both the first event and subsequent recurrences-has become a central therapeutic goal to prolong survival. The ...
Response to Comment on "Loss of Mtarc1 Protects Against Steatotic Liver Disease in Mice" [0.03%]
对“Mtarc1丢失可保护小鼠发生脂肪变性肝病”一文的回应
Xiaofei Yin,Patrick T Ellinor
Xiaofei Yin
Vaccines at the Heart of Hepatitis Elimination: Insights From the ESCMID Study Group for Viral Hepatitis (ESGVH) [0.03%]
疫苗在消除肝炎中的核心作用：来自欧洲临床微生物学和传染病学会病毒性肝炎研究组（ESGVH）的见解
Oana Săndulescu,Gülşen Özkaya Şahin,Susanne Gjeruldsen Dudman et al.
Oana Săndulescu et al.
The global elimination of viral hepatitis by 2030 remains an ambitious goal that hinges not only on diagnostics and therapeutics but fundamentally on the strategic use and continued innovation of vaccines. The ESCMID Study Group for Viral H...
Sex Differences in Liver Cancer Mortality Trends in the US: Role of Cancer Type, Aetiology, and Birth Cohort [0.03%]
美国肝癌死亡率的性别差异：癌症类型、病因和出生队列的作用
Ugo Fedeli,Sara Battistella,Elisa Pinto et al.
Ugo Fedeli et al.
Background and aims: Liver cancer mortality (HCC, iCCA) is rising in the U.S., with marked sex disparities linked to hormones and risk factor exposure. This study examines recent trends in mortality by subtype, aetiology,...
Prevalence and Risk Factors of Elevated Alanine Aminotransferase (ALT) in 2382 Treatment-naïve HBV/HDV Co-Infected Patients [0.03%]
2382例初治乙肝和丁肝病毒合并感染患者的血清谷丙转氨酶升高水平及其影响因素分析
Habiba Kamal,Ganbolor Jargalsaikhan,Sanjaasuren Enkhtaivan et al.
Habiba Kamal et al.
Background: Chronic hepatitis D (CHD) causes severe chronic hepatitis. Knowledge is limited about factors correlating with ALT in treatment-naïve patients with CHD. This study analysed the pattern and determinants of ALT...
Impact of Documented Social Vulnerability on Clinical Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease [0.03%]
社会脆弱性对代谢功能异常相关肝脂肪变性疾病临床结局影响的研究
Pojsakorn Danpanichkul,Yanfang Pang,Maria Inggriani et al.
Pojsakorn Danpanichkul et al.
Background: Social determinants of health (SDoH), including poverty and social isolation, have emerged as important contributors to adverse outcomes of chronic diseases. However, their impact on patients with metabolic dy...
Saroglitazar 4 Mg in Metabolic Dysfunction-Associated Steatotic Liver Disease: 24-Week Results From Phase 4 Study [0.03%]
用于代谢性肝病的萨羅格列扎爾：Phase 4研究24周結果
Arun Sanyal,Soham Doshi,Nitin Behl et al.
Arun Sanyal et al.
Background and aims: Saroglitazar magnesium, a dual PPAR α/γ agonist, is approved in India for the treatment of non-alcoholic fatty liver disease (NAFLD), now known as metabolic dysfunction-associated steatotic liver di...